Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsSolid TumorsProtocol groupAcute LeukemiasAggressive LymphomasCellular TherapyHodgkin LymphomaIndolent LymphomasNeuro-OncologyradiotherapyT-Cell and NK-Cell NeoplasmsTransplantationDiseaseAcute Lymphoblastic LeukaemiaCAR T-Cell TherapyChronic Lymphocytic Leukemia / Small Lymphocytic LymphomaHodgkin LymphomaMalignant MeningitisMantle Cell LymphomaNHL, B-Cell Type, Anaplastic Large Cell Lymphoma, ALK-PositiveNHL, B-Cell Type, Burkitt's LymphomaNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular Grade I-IIIaNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, IndolentNHL, B-Cell Type, Lymphoplasmocytic / Waldenström's diseaseNHL, B-Cell Type, Marginal Zone LymphomaNHL, B-Cell Type, Mediastinal (Thymic) Large B-Cell LymphomaNHL, T-Cell Type, Anaplastic Large CellNHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK-positiveNHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK negativeNHL, T-Cell Type, AngioimmunoblasticNHL, T-Cell Type, Enteropathy TypeNHL, T-Cell Type, HepatosplenicNHL, T-Cell Type, Other Specified Leukemias, Aggressive NK-Cell LeukemiaNHL, T-Cell Type, Peripheral, UnspecifiedPrimary Lymphoma of the CNSSubgroupCD20+Lymphomatous MeningitisICD10C79.3C81.-C82.-C82.7C82.9C83.-C83.0C83.1C83.3C83.7C84.4C84.6C84.7C85.2C85.9C86.1C86.2C86.5C88.0-C91.0-C91.1-C94.7-MeSHLeukemia, Lymphocytic, Chronic, B-CellLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLymphoma, Mantle-CellLymphoma, T-CellLymphoma, T-Cell, PeripheralMeningeal CarcinomatosisPrecursor B-Cell Lymphoblastic Leukemia-LymphomaWaldenstrom MacroglobulinemiaSequenceEPCO(0.16/0.8/48), DLBCL, C1 (PID2486) -|- EPCO48, C2-3 (PID2487) -|- EPCO48, C4-9 (PID2488) -|- EPCO48, C10+ (PID2489)IXAZ4/RITU1400/DEXA20, Waldenström (PID2025) -|- (PID2026) -|- (PID2027) -|- (PID310)LOTIS-2: -|- LONTES150, DLBCL, C1-2 (PID2229) -|- LONTES75, DLBCL, C3+ (PID2230)MOR208: TAFA12/LENA25, DLBCL, C1 (PID1848) -|- C2-3 (PID1849) -|- C4-12 (PID1850) -|- C13+ (PID1851)MOSU(1/2/60), B-NHL, C1 (PID2105) -|- C2 (PID2106) -|- C3+ (PID2107)OBIN1000/GLOF(2.5/10), DLBCL, C1 (PID2393) -|- GLOF30, C2-12 (PID2394)OFAR (OXAL25/FLUD30/CYTA1000/RITU375), CLL (Richter Syndrome), C1 (PID828) -|- C2+ (PID829)POLARIX: Pola-R-CHP (POLVED1,8/RITU375/CYCL750/DOXO50/PRED100), DLBCL, C1-6 (PID1920) -|- RITU375, C7-8 (PID1921)R-ACVBP (RITU375/DOXO75/CYCL1200/VIND2/BLEO10/PRED60) ind., DLBCL A (PID340) -|- cons., B (PID341) -|- cons., C (PID342) -|- cons., D (PID343)R-CHOP 14 (RITU375/CYCL750/DOXO50/VNCR2/PRED100), DLBCL, C1-6 (PID112) -|- RITU375, C7-8 (PID1448)R-CHOP 14 smart (RITU375/CYCL750/DOXO50/VNCR2/PRED100), DLBCL, C1 (PID926) -|- C2 (PID929) -|- C3 (PID930) -|- C4 (PID929) -|- C5 (PID930) -|- C6 (PID929) -|- C7+ (PID75)R-CHOP 21 (RITU375/CYCL750/DOXO50/VNCR2/PRED100)/MTRX12, Testicular Lymphoma, C1 (PID901) -|- C2 (PID902) -|- C3-6 (PID903)R-ICE (RITU375/ETOP100/CRBP5/IFOS5), DLBCL, C1 (PID348) -|- C2+3 (PID349)RITU375/PGLDX30/CYCL750/VNCR2/PRED40, DLBCL, C1 (PID2502) -|- C2-6 (PID2503)RITU375/POLVED1.8/BEND90, DLBCL, C1 (PID1422) -|- C2-6 (PID1423)STUDY - levelSTUDY OPTIMAL, Arm F-ASTUDY OPTIMAL, Arm F-BSTUDY OPTIMAL, Arm LF-ASTUDY OPTIMAL, Arm LF-BSTUDY OPTIMAL, Arm LF-CSTUDY OPTIMAL, Arm LF-DVNCR1/PRED60, DLBCL (PID1778) -|- C1 (PID2535) -|- C2-6 (PID2536)ChemotherapyChemo-substanceBendamustineBleomycinCarboplatinCarmustineCisplatinCyclophosphamideCytarabineDexamethasoneDoxorubicinDoxorubicin liposomalDoxorubicin pegylated liposomalEpcoritamabEtoposideFludarabineGemcitabineGlofitamabIfosfamideLenalidomideLoncastuximab TesirinMelphalanMethotrexateMethylprednisoloneMitoxantroneMosunetuzumabNivolumabObinutuzumabOxaliplatinPixantronPolatuzumab vedotinPrednisoloneProcarbazineRituximabSelinexorTafasitamabVincristineVincristine liposomalVindesineChemo-substanceBendamustineBleomycinCarboplatinCarmustineCisplatinCyclophosphamideCytarabineDexamethasoneDoxorubicinDoxorubicin liposomalDoxorubicin pegylated liposomalEpcoritamabEtoposideFludarabineGemcitabineGlofitamabIfosfamideLenalidomideLoncastuximab TesirinMelphalanMethotrexateMethylprednisoloneMitoxantroneMosunetuzumabNivolumabObinutuzumabOxaliplatinPixantronPolatuzumab vedotinPrednisoloneProcarbazineRituximabSelinexorTafasitamabVincristineVincristine liposomalVindesineChemo-substanceBendamustineBleomycinCarboplatinCarmustineCisplatinCyclophosphamideCytarabineDexamethasoneDoxorubicinDoxorubicin liposomalDoxorubicin pegylated liposomalEpcoritamabEtoposideFludarabineGemcitabineGlofitamabIfosfamideLenalidomideLoncastuximab TesirinMelphalanMethotrexateMethylprednisoloneMitoxantroneMosunetuzumabNivolumabObinutuzumabOxaliplatinPixantronPolatuzumab vedotinPrednisoloneProcarbazineRituximabSelinexorTafasitamabVincristineVincristine liposomalVindesineChemo-substanceBendamustineBleomycinCarboplatinCarmustineCisplatinCyclophosphamideCytarabineDexamethasoneDoxorubicinDoxorubicin liposomalDoxorubicin pegylated liposomalEpcoritamabEtoposideFludarabineGemcitabineGlofitamabIfosfamideLenalidomideLoncastuximab TesirinMelphalanMethotrexateMethylprednisoloneMitoxantroneMosunetuzumabNivolumabObinutuzumabOxaliplatinPixantronPolatuzumab vedotinPrednisoloneProcarbazineRituximabSelinexorTafasitamabVincristineVincristine liposomalVindesineNo. Substances123456 RadiotherapySupportive therapySupportive substanceAciclovirAllopurinolAmphotericin BAprepitantBalanced Crystalloid SolutionCimetidineCiprofloxacinCotrimoxazoleDexamethasoneDextrose 5%DimetindenFamotidineFilgrastimFolinic acidFosaprepitantFurosemideGranisetronLipegfilgrastimMagnesiumMagnesium sulfateMesnaNaCl 0.9%PalonosetronParacetamolPegfilgrastimPotassium chloridePrednisolonePyridoxineSodium BicarbonateSupportive substanceAciclovirAllopurinolAmphotericin BAprepitantBalanced Crystalloid SolutionCimetidineCiprofloxacinCotrimoxazoleDexamethasoneDextrose 5%DimetindenFamotidineFilgrastimFolinic acidFosaprepitantFurosemideGranisetronLipegfilgrastimMagnesiumMagnesium sulfateMesnaNaCl 0.9%PalonosetronParacetamolPegfilgrastimPotassium chloridePrednisolonePyridoxineSodium BicarbonateSupportive substanceAciclovirAllopurinolAmphotericin BAprepitantBalanced Crystalloid SolutionCimetidineCiprofloxacinCotrimoxazoleDexamethasoneDextrose 5%DimetindenFamotidineFilgrastimFolinic acidFosaprepitantFurosemideGranisetronLipegfilgrastimMagnesiumMagnesium sulfateMesnaNaCl 0.9%PalonosetronParacetamolPegfilgrastimPotassium chloridePrednisolonePyridoxineSodium BicarbonateSupportive substanceAciclovirAllopurinolAmphotericin BAprepitantBalanced Crystalloid SolutionCimetidineCiprofloxacinCotrimoxazoleDexamethasoneDextrose 5%DimetindenFamotidineFilgrastimFolinic acidFosaprepitantFurosemideGranisetronLipegfilgrastimMagnesiumMagnesium sulfateMesnaNaCl 0.9%PalonosetronParacetamolPegfilgrastimPotassium chloridePrednisolonePyridoxineSodium BicarbonateNo. Substances123456789101112Protocol classificationTherapy classificationalternativecurrent standardolder age and/or reduced general conditionstudy analogStudy protocol, currentIntensityDose intensifiedhigh doseStandard doseTherapy indicationFirst lineRefractory diseaseRelapse therapySecond lineseveral possibleThird line Therapy phaseConsolidationInductionMaintenancePre-phaseReinductionSalvageTherapy intentioncurativecurative or palliativedisease controlpalliativeRisksAlopeciaAnemia Hb below 8g/dlAnemia Hb below 10g/dlAstheniaBleedingCardiotoxicityConstipationCytokine Release SyndromeDiarrheaDyspneaEdemaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaGastrointestinal ToxicityHeadacheHemorrhageHepatotoxicityHerpes ZosterHyperglycemiaHypertensionHypoalbuminemiaHypocalcemiaHypokalemiaHypomagnesemiaHypophosphatemiaIncrease AminotransferasesInfectionsLeukopeniaLymphopeniaMucositisMyalgiasNeuropathyNeurotoxicityNeutropeniaOral MucositisPainPhotosensitivityPneumoniaPruritusPyrexiaRashRenal FailureSepsisThrombocytopenia below 50 000/µlThromboembolic EventTumor Lysis SyndromeUpper Respiratory Tract InfectionVenous ThrombosisVomiting only studiesPublicationAuthorAbramson JAydin SBias PBudde LEChao NJCoiffier 2002Crump MDavies ADickinson MJDuell JEl Gnaoui TFields PAFurqan FGisselbrecht CGopal AHeld GHerbrecht RKalakonda NKirschey SLiu E Luminari SMartin AMoccia AAOberic L Pettengell RPeyrade FPfreundschuhPfreundschuh MRodriguez MARubenstein JRécherSchmitz NSchuster SJSehn LStorti STessoulin BThieblemont CTilly HTsimberidou AVelasquez WSVitolo UWeidmann EZaja FDiseaseAggr. B-NHL, Rezidiv oder therapierefraktäraggr. B-NHL incl. DLBCL, nach Rezidiv oder bei fehlendem CR unter Erstlinie mit CHOP, ECOG 0-1Aggr. B-NHL über 80 Jahre oder unter 80 mit KI gegen R-CHOP, ErstlinieAggr. oder de novo transf. B-NHL, Rezidiv - Drittlinie und höher, ECOG 0-2aggressive, CD 20+ B-NHL, 18-60 Jahre, Erstlinie, ECOG 0-3Aggressive B-NHL, Patienten zwischen 65 und 85 Jahren, ECOG 0-2aggressive CD20+ B-NHL, 61-80 Jahre, ECOG 0-1aggressive CD20+ B-NHL, 61-80 Jahre, ECOG 0-4aggressive CD20+ B-NHL, 61-80 Jahre, Hochrisiko-Patienten, ECOG 0-1Aggressives B-NHL, 61-80 Jahre, Erstlinie, ECOG 0-2B-NHL, refraktär oder rezidivierend, ohne Eignung zur HochdosistherapieB-NHL, rezidiviert oder therapierefraktär, CD19- positiv, Lymphodepletion vor CAR T-Zell TherapieB-Non-Hodgkin-Lymphom/Hodgkin LymphomCoiffier 2002: DLBCL, 60-80 Jahre, ECOG 0-2, Erstlinie , Cunningham 2013: DLBCL, ab 18 Jahren, ECOG 0-3, Erstlinie.diffus großzelliges B-Non-Hodgkin-Lymphom, 2-5 Vortherapien, nicht geeignet für autologe SCT, ECOG 0-2diffus großzelliges Non-Hodgkin-Lymphom, HochrisikoDLBCL, 60-75 J., ErstlinieDLBCL, Ann-Arbor II-IV, CR oder PR nach 6-8 Zyklen R-CHOP, 60-80 J., ECOG 0-2DLBCL, Ann Arbor Stadium I-IV, über 80 J., ECOG 0-2DLBCL, Erstlinie, bis 59 JahreDLBCL, Erstlinie, IPI 2-5, ECOG 0-2DLBCL, Erstlinie, Kontraindikation für AnthrazyklineDLBCL, kardiale Komorbiditäten mit Kontraindikation für die Anthrazyklingabe, ErstlinieDLBCL, Kontraindikation für AnthrazyklineDLBCL, rezidiviert oder therapierefraktär, mind. 2 VortherapienDLBCL, Rezidiv nach mind. 2 Vortherapien, ASCT ungeeignet oder bereits unterzogen, Lymphodepletion vor CAR-T-Zell TherapieDLBCL, Rezidiv nach mind. 2 Vortherapien, ASCT ungeeignet oder bereits unterzogen, Lymphodepletion vor CAR T-Zell TherapieDLBCL, Rezidiv oder refraktär, mit mindestens einer anthrazyklinhaltigen VortherapieDLBCL, Stadium II - IV, CD20+, Erstlinie, ECOG 0-2DLBCL, über 80 Jahre, ECOG 0-2, ErstlinieDLBCL Stadium I-IV, älter als 60 Jahre, Erstlinie, ECOG 0-2Fludarabin-refraktäre CLL oder Transormation zum Richter Syndrom, ECOG 0-2Hodenlymphom, Stadium I-II, ECOG 0-1Lymphom, rezidiviert oder therapierefraktärLymphom, Rezidiv oder refraktär, mit mindestens einer anthrazyklinhaltigen VortherapieNon-Hodgkin-Lymphom / Hodgkin LymphomR/R DLBCL, mindestens 1 Vortherapie, ECOG 0-2, nicht geeignet für eine ASCT, periphere Neuropathie bis Grad 1Refraktäres oder rezidivierendes Non-Hodgkin-Lymphomrezidivierendes (erstlinie mit Anthrazyklin) oder fortschreitendes aggressives NHL, > 65 Jahre oder >18 mit HCT-Cl score > 2, ECOG 0-2rezidivierendes oder fortschreitendes aggressives NHL, > 65 Jahre oder >18 mit HCT-Cl score > 2rezidivierendes oder refraktäres Non-Hodgkin-Lymphom, ECOG 0-2rezidivierte aggressive B-NHL, 18-65 Jahre, ECOG 0-2Rezidivierte oder refraktäre, aggressive Lymphome, 2. Linie vor ASCT, ECOG 0-3Rezidiviertes DLBCL, 1-3 Vortherapien, ungeeignet für eine ASCTrezidiviertes oder refraktäres B-NHL, mindestens zwei vorherige systemische BehandlungenRezidiviertes und therapierefraktäres DLBCL, 1-3 Vortherapien, ECOG 0-1Rezidiviertes und therapierefraktäres DLBCL, FL Grad 3b, mind. 2 Vortherapien, ECOG 0-2unbehandeltes diffus großzelliges B-Non-Hodgkin Lymphom bei älteren, gebrechlichen Patienten (>70 Jahre)Wiederkehrendes oder refraktäres ZNS Lymphom primär oder NHL, CD20+, PS über 50OriginAbramson Cancer Center, University of Pennsylvania, Philadelphia, JULIET trialAbteilung für Hämatologie, Universität Duisburg-Essen, DeutschlandAVOID Neutropenia, Merckle GmbHBattista Hospital and University, Turin, IELSG-10BC Cancer and The University of British Columbia, Vancouver, BC, CanadaCancer Center, Massachusetts General Hospital, BostonCancer Research UK Centre, University of Southampton, UK, SABRINA StudieC Cancer Centre for Lymphoid Cancer and The University of British Columbia, Vancouver, British Columbia, CanadaCentre Antoine Lacassagne, Nice, France, LYSA groupCentre Henri-Becquerel, Rouen Cedex, France, POLARIX trialCity of Hope National Medical Center, Duarte, CADepartment of Clinical Hematology, Henri Mondor Hospital, Créteil, FrankreichDepartment of Haematology, Oncology and Pneumology, University Medical School of the Johannes Gutenberg University MainzDepartment of Haematology, St George's Hospital, University of London, EnglandDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USADepartment of Medicine, Stanford University School of Medicine, CADepartment of Oncology and Hematology, Hôpital de Hautepierre, Strasbourg, France, PIX203 trialDepartments of Leukemia and Experimental Therapeutics, The University of Texas, Anderson Cancer Center Departments of Leukemia and Experimental Therapeutics, The University of Texas, Anderson Cancer Center HoustonDivision of Hematology Oncology, University of California; Memorial Sloan-Kettering Cancer Center, New YorkDSHNHL 2002-1DSHNHL 2009-1, OPTIMAL > 60Euro18-trial Department of Oncology and Haematology, University of Modena and Reggio Emilia, Modena Cancer Center, ItalyGEL/TAMO cooperative groupe, SpanienGerman High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL), RICOVER-60Groupe d'Etude des Lymphomes de l'Adulte (GELA) investigatorsGroupe d'Etude des Lymphomes de l'Adulte (GELA) investigators LNH03-2BGuys and St Thomas Hospital, London, United KingdomHematology, Universita Cattolica Sacro Cuore Campobasso, Campobasso, ItalyHopital Saint-Louis, Hemato-oncologie, Universite de Paris, Paris, FranceHopital Saint-Louis, Paris, FranceHopital Saint Louis, Paris, Frankreich, CORAL StudieHospices Civils de Lyon, Université Claude Bernard, FrankreichInstitut Universitaire du Cancer, Toulouse-Oncopole, Toulouse, FranceInternal Medicine I Saarland University Medical School, DSHNHL 2015-1Klinik für Onkologie und Hämatologie, Krankenhaus Nordwest, Frankfurt am Main, DeutschlandMedical College of Wisconsin, Milwaukee, USAMedizinische Klinik und Poliklinik II, Universitätsklinik Würzburg, Würzburg, Germany, L-MIND studyNantes Medical University, Nantes, FrancePeter MacCallum Cancer Centre, Melbourne, AustraliaPrincess Margaret Cancer Centre, Ontario, CanadaSection of Lymphoma, M.D. Anderson Cancer Center, Houston, TXUniversity Hospital, Udine, ItalyUniversity of Liverpool, Liverpool, UK, SADAL trialUniversity of Texas M.D. Anderson Cancer Center, HoustonUniversity of Texas M.D. Anderson Cancer Center, Houston, USAUniversity of Washington/Fred Hutchinson Cancer Research Center, Seattle, WAUniversitätsklinikum des Saarlandes, Homburg, SMARTE-R-CHOP-14 Trial, DSHNHLProtocols in Revision 95 protocols foundProtocols under revision.Bendamustine 90, diffuse large B-non-Hodgkin Lymphoma, Lymphodepletion (PID1830)DHAC - Carboplatin 5 / Cytarabine 2000 / Dexamethasone 40, Non-Hodgkin Lymphoma / Hodgkin Lymphoma. (PID2346)Epcoritamab (0.16/0.8/48), diffuse large B-non-Hodgkin Lymphoma, Cycle 1 (PID2486)Epcoritamab 48, diffuse large B-non-Hodgkin Lymphoma, cycle 10+ (PID2489)Epcoritamab 48, diffuse large B-non-Hodgkin Lymphoma, Cycle 2-3 (PID2487)Epcoritamab 48, diffuse large B-non-Hodgkin Lymphoma, cycle 4-9 (PID2488)ESHAP - Etoposide 40 / Cisplatin 25 / Cytarabine 2000 / Methylprednisolone 375, Non-Hodgkin Lymphoma. (PID2348)Fludarabine 25 / Cyclophosphamide 250, diffuse large B-non-Hodgkin Lymphoma, Lymphodepletion (PID1829)Fludarabine 30 / Cyclophosphamide 300, B-non-Hodgkin Lymphoma, Lymphodepletion (PID2471)Glofitamab 30, diffuse large B-non-Hodgkin Lymphoma, cycle 2-12 (PID2394)Lenalidomide 25, diffuse large B-Non-Hodgkin Lymphoma, maintenance (PID2504)Loncastuximab Tesirin 150, diffuse large B-non-Hodgkin Lymphoma, cycle 1-2 (PID2229)Loncastuximab Tesirin 75, diffuse large B-non-Hodgkin Lymphoma, cycle 3+ (PID2230)Methotrexate 500/3000, CNS Prophylaxis, Malignant Meningitis (PID1001)MINE (Ifosfamide 1.33 / Mitoxantrone 8 / Etoposide 65), B-non-Hodgkin Lymphoma. (PID2389)Mosunetuzumab (1/2/60), B-Non-Hodgkin Lymphoma, cycle 1 (PID2105)Mosunetuzumab 30, B-Non-Hodgkin Lymphoma, cycle 3+ (PID2107)Mosunetuzumab 60, B-Non-Hodgkin lymphoma, cycle 2 (PID2106)Obinutuzumab 1000 / glofitamab (2.5/10), diffuse large B-non-Hodgkin Lymphoma, cycle 1 (PID2393)OFAR - Oxaliplatin 25 / Fludarabine 30 / Cytarabine 1000 / Rituximab 375, Chronic Lymphocytic Leukemia, Richter Syndrome, cycle 1 (PID828)OFAR - Oxaliplatin 25 / Fludarabine 30 / Cytarabine 1000 / Rituximab 375, Chronic Lymphocytic Leukemia, Richter Syndrome, cycle 2+ (PID829)Pixantron 50, diffuse large B-non-Hodgkin Lymphoma (PID360)Pola-R-CHP - Polatuzumab Vedotin 1.8 / Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, cycle 1-6 (PID1920)Pola-R-CHP - Rituximab 375, Diffuse Large B-Non-Hodgkin Lymphoma, cycle 7-8. (PID1921)R- Benda - Rituximab 375 / Bendamustine 120, diffuse large B-non-Hodgkin Lymphoma (PID338)R- Benda - Rituximab 375 / Bendamustine 90, diffuse large B-non-Hodgkin Lymphoma (PID1159)R- ICE - Rituximab 375 / Etoposide 100 / Carboplatin 5 / Ifosfamide 5, diffuse large B-non-Hodgkin Lymphoma, Cycle 1 (PID348)R- ICE - Rituximab 375 / Etoposide 100 / Carboplatin 5 / Ifosfamide 5, diffuse large B-non-Hodgkin Lymphoma, cycle 2+3 (PID349)R-ACVBP - Cytarabine 100 consolidation, diffuse large B-non-Hodgkin Lymphoma Part D (PID343)R-ACVBP - high-dose Methotrexate 3000, diffuse large B-non-Hodgkin Lymphoma, consolidation, part B (PID341)R-ACVBP - Rituximab 375 / Doxorubicin 75 / Cyclophosphamide 1200 / Vindesin 2 / Bleomycin 10 / Prednisolone 60, induction, diffuse large B-non-Hodgkin Lymphoma Part A (PID340)R-ACVBP - Rituximab 375 / Ifosfamide 1.5 / Etoposide 300 consolidation, diffuse large B-non-Hodgkin Lymphoma Part C (PID342)R-ASHAP - Rituximab 375 / Doxorubicin 10 / Cisplatin 25 / Cytarabine 2000 / Methylprednisolone 375, diffuse large B-non-Hodgkin Lymphoma (PID359)R-CEPP - Rituximab 375 / Cyclophosphamide 600 / Etoposide 70 / Procarbazine 60 / Prednisolone 60, diffuse large B-Non-Hodgkin Lymphoma (PID2508)R-CHOEP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Etoposide 100 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma (PID722)R-CHOP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, cycle 1-6 (PID112)R-CHOP 14 - Rituximab 375, diffuse large B-non-Hodgkin Lymphoma, cycle 7-8 (PID1448)R-CHOP 21 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100 / Methotrexate 12, Testicular Lymphoma, Cycle 1 (PID901)R-CHOP 21 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100 / Methotrexate 12, Testicular Lymphoma, Cycle 2 (PID902)R-CHOP 21 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, Testicular Lymphoma, Cycle 3-6 (PID903)R-CHOP 21 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 40, diffuse large B-non-Hodgkin Lymphoma (PID113)R-COEP - Rituximab 375 / Cyclophosphamide 750 / Etoposide (50/100) / Vincristine 2 / Prednisolone 45, diffuse large B-non-Hodgkin Lymphoma (PID1777)R-COMP 21 - Rituximab 375 / Cyclophosphamide 750 / Vincristine 2 / lip. doxorubicin 50 / Prednisolone 100, diffuse large B-cell lymphoma (PID125)R-CPOP 21 - Rituximab 375 / Cyclophosphamide 750 / Pixantron 88 / Vincristine 2 / Prednisolone 40, diffuse large B-non-Hodgkin Lymphoma (PID931)R-DexaBEAM - Rituximab 375 / Dexamethasone 8 / Carmustine 60 / Etoposide 75 / Cytarabine 100 / Melphalan 20, B-Non-Hodgkin Lymphoma (PID1006)R-DHAC - Rituximab 375 / Carboplatin 5 / Cytarabine 2000 / Dexamethasone 40, B-Non-Hodgkin's Lymphoma/Hodgkin's Lymphoma (PID2345)R-DHAP - Rituximab 375 / Cisplatin 100 / Cytarabine 2000 / Dexamethasone 40, diffuse large B-non-Hodgkin Lymphoma (PID350)R-ESHAP - Rituximab 375 / Etoposide 40 / Cisplatin 25 / Cytarabine 2000 / Methylprednisolone 250, diffuse large B-non-Hodgkin Lymphoma (PID358)R-GCVP - Rituximab 375 / Gemcitabine 750 / Cyclophosphamide 750 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma (PID1774)R-GDC - Rituximab 375 / Gemcitabine 1000 / Dexamethasone 40 / Carboplatin 5, diffuse large B-non-Hodgkin Lymphoma (PID1681)R-GDP - Rituximab 375 / Gemcitabine 1000 / Dexamethasone 40 / Cisplatin 75, diffuse large B-non-Hodgkin Lymphoma (PID605)R-miniCHOP - Rituximab 1400 / Cyclophosphamide 400 / Doxorubicin 25 / Vincristine 1 / Prednisolone 40, diffuse large B-Non-Hodgkin Lymphoma, cycle 2-6, variant 1 (PID2536)R-miniCHOP - Rituximab 375 / Cyclophosphamide 400 / Doxorubicin 25 / Vincristine 1 / Prednisolone 40, diffuse large B-non-Hodgkin Lymphoma (PID339)R-miniCHOP - Rituximab 375 / Cyclophosphamide 400 / Doxorubicin 25 / Vincristine 1 / Prednisolone 40, diffuse large B-Non-Hodgkin Lymphoma, cycle 1, variant 1 (PID2535)Rituximab 1400, single dose subcutaneous (PID310)Rituximab 25, Malignant Meningitis (PID2571)Rituximab 375 / Bendamustine 120 / Carboplatin 5 / Etoposide 100, B-Non-Hodgkin Lymphoma. (PID2390)Rituximab 375 / Gemcitabine 1000 / Oxaliplatin 100, B-non-Hodgkin Lymphoma (PID354)Rituximab 375 / Doxorubicin Liposomal 30 / Cyclophosphamide 750 / Vincristine 2 / Prednisolone 40, diffuse large B-Non-Hodgkin Lymphoma, cycle 1 (PID2502)Rituximab 375 / Doxorubicin Liposomal 30 / Cyclophosphamide 750 / Vincristine 2 / Prednisolone 40, diffuse large B-Non-Hodgkin Lymphoma, cycle 2-6 (PID2503)Rituximab 375 / Polatuzumab Vedotin 1.8 / Bendamustine 90, diffuse large B-non-Hodgkin Lymphoma, cycle 2-6 (PID1423)Rituximab 375 / Polatuzumab Vedotin 1.8 / Bendamustine 90, diffuse large B-non-Hodgkin Lymphoma, cycle 1 (PID1422)Selinexor 60, diffuse large B-non-Hodgkin Lymphoma (PID1796)SMARTE- R-CHOP 14 - Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, cycle 2,4,6 (PID929)SMARTE- R-CHOP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, Cycle 1 (PID926)SMARTE- R-CHOP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, cycle 3.5 (PID930)SMARTE- R-CHOP 14 - Rituximab 375, diffuse large B-non-Hodgkin Lymphoma, cycle 7+ (PID75)Study - Level - Gemcitabine 1000 / Oxaliplatin 100, Aggressive Non-Hodgkin Lymphoma (PID972)Study - Level - Nivolumab 3 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-non-Hodgkin Lymphoma, Cycle 1 (PID968)Study - Level - Nivolumab 3 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-non-Hodgkin Lymphoma, Cycle 2+ (PID970)Study - Level - Nivolumab 3 / Rituximab 375 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-non-Hodgkin Lymphoma, Cycle 1 (PID967)Study - Level - Nivolumab 3 / Rituximab 375 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-non-Hodgkin Lymphoma, Cycle 2+ (PID969)Study - Level - Nivolumab 3, diffuse large B-non-Hodgkin Lymphoma, consolidation (PID971)Study - Level - Rituximab 375 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-non-Hodgkin Lymphoma, Cycle 1 (PID973)Study - Level - Rituximab 375 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-non-Hodgkin Lymphoma, Cycle 2+ (PID974)Study - OPTIMAL - Arm F-A, R-CHOP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma (PID1124)Study - OPTIMAL - Arm F-B, R-CHLIP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine Liposomal 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma (PID1123)Study - OPTIMAL - Arm LF-A, R-CHOP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma (PID1121)Study - OPTIMAL - Arm LF-B, R-CHLIP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine Liposomal 1.67 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma (PID1122)Study - OPTIMAL - Arm LF-C optimised, CHOP 14 - Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, Cycle 6 (PID1131)Study - OPTIMAL - Arm LF-C optimised, R-CHOP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, Cycle 1 (PID1126)Study - OPTIMAL - Arm LF-C optimised, R-CHOP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, cycle 2-5 (PID1127)Study - OPTIMAL - Arm LF-D optimised, CHLIP 14 - Cyclophosphamide 750 / Doxorubicin 50 / Vincristine liposomal 1.67 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, Cycle 6 (PID1130)Study - OPTIMAL - Arm LF-D optimised, R-CHLIP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine Liposomal 1.67 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, Cycle 1 (PID1125)Study - OPTIMAL - Arm LF-D optimised, R-CHLIP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine Liposomal 1.67 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, cycle 2-5 (PID1128)Study - OPTIMAL - Rituximab 375 / high dose Methotrexate 3000, diffuse large B-non-Hodgkin Lymphoma, CNS Prophylaxis (PID1133)Study - OPTIMAL - Pre-phase, Diffuse Large B-Non-Hodgkin Lymphoma (PID1120)Avoid study - R-CHOP 21 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma (PID706)Study-OPTIMAL - Rituximab 375, DLBCL (PID1132)Tafasitamab 12 / Lenalidomide 25 - Tafasitamab 12, maintenance, diffuse large B-non-Hodgkin Lymphoma, cycle 13+ (PID1851)Tafasitamab 12 / Lenalidomide 25, diffuse large B-non-Hodgkin Lymphoma, cycle 1 (PID1848)Tafasitamab 12 / Lenalidomide 25, diffuse large B-non-Hodgkin Lymphoma, cycle 2-3 (PID1849)Tafasitamab 12 / Lenalidomide 25, diffuse large B-non-Hodgkin Lymphoma, cycle 4-12 (PID1850)Vincristine 1 / Prednisolone 100, Pre-phase, diffuse large B-non-Hodgkin Lymphoma (PID69)Vincristine 1 / Prednisolone 60, diffuse large B-non-Hodgkin Lymphoma (PID1778)